Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study
NCT ID: NCT05850832
Last Updated: 2023-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2022-10-05
2023-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Effects of Intravenous Magnesium Sulphate on Anaesthesia and Analgesia in Elective General Surgery Patients
NCT05598307
Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
NCT02669368
Adding Magnesium Sulfate to Bupivacaine in Ultrasound Guided Paravertebral Block for Laparoscopic Cholecystectomy
NCT05099250
Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy
NCT02533284
Effect of Single Dose Intravenous Magnesium Sulfate on Postoperative Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy
NCT07328893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following attaining Ethical committee approval and patient's written consent- after broad explanation of the entire procedure- 60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study.
Exclusion criteria were: patients on chronic use or known allergic to the study drugs, body mass index \>35 kg/m2, significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases, liver or renal disease, known asthma or reactive airway diseases.
Preoperatively all participants were carefully evaluated via detailed history taking, thorough physical examination and routine investigations (complete blood picture, renal function tests and liver functions). Also, they were instructed in the utilization of the verbal rating scale (VRS).
For blinding purpose, both the study drugs were prepared by an anaesthesiologist not enrolled in data assumption. Accordingly, for every case 2 prefilled syringes; one 10-ml for loading dose and the other 20-ml for maintenance infusion were given unidentified to the operating theater containing either Esmolol (Esmolol hydrochloride; Baxter Healthcare Corp., Deerfield, USA) or MgSo4 ( Egyptian international pharmaceutical indust., EYGPT).
Randomization was achieved prior to the study by means of randomization table prepared by computer software to assign the number of cases among the studied groups. Patients were randomly allocated using closed envelopes method into 2 equal groups (n=30 each):
* Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
* Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Loading dose was given after fentanyl injection and before propofol induction. Maintenance dose was continued until the end of the procedure.
No premedication was offered. On arrival to the operating room, an intravenous cannula was placed and secured before induction of anaesthesia and all patients were attached to standard monitors including pulse oximetry, ECG, non- invasive blood pressure and end tidal carbon dioxide (ETCO2) monitor (Datex ohmeda S/5).
Anaesthesia was induced with 1 μg/kg fentanyl and 1.5 - 2 mg/kg propofol till cessation of verbal contact. Cisatracurium 0.15 mg/kg was used for neuromuscular relaxation and endotracheal intubation (via 8 or 8.5 mm for males, 7 or 7.5 mm for female patients, high-volume/low pressure portex endotracheal tubes). Soon after induction, in both groups IV dexamethasone 8 mg was given and 1 g paracetamol IV was infused over 15 mins. Anaesthesia was maintained with sevoflurane 1-2 % with 50 % oxygen in air. Increments of IV fentanyl 0.5 µg/kg was given for analgesia if systolic blood pressure or heart rate was increased by more than 20 % of baseline level, also incremental dose of cisatracurium 0.03 mg/kg was used to maintain muscle relaxation according to nerve stimulation. Patients were mechanically ventilated to maintain ETCO2 between 33-35 mmHg and an oxygen saturation of 98 %. The port sites were infiltrated by the surgical team with 3ml of 0.25% bupivacaine. Pneumoperitoneum with carbon dioxide was achieved, maintaining the intraabdominal pressure at 12 mm Hg throughout surgery. Patients were positioned in 30 degrees anti-Trendelenburg position and rotated toward the left side to facilitate exposure of the gall bladder. IV warmed 0.9 % NaCL was given during surgery at a rate 6 ml/kg/hr. If required, intraoperative hypotension (mean arterial blood pressure lower than 50 mm Hg) and bradycardia (heart rate \< 40 bpm) were managed in both groups with i.v ephedrine and atropine respectively. At the end of surgery, patients were returned to the supine position and the Co2 left in the peritoneal cavity was expelled by abdominal compression slowly. 0.25 % bupivacaine was injected again at the surgical incisions. Esmolol and Mgso4 infusions were stopped and discarded at end of the procedure, which was marked at the end of skin closure and wound coverage. Anaesthesia was discontinued and 100 % oxygen was administrated. Reversal of muscle relaxants by i.v neostigmine 0.04-0.08 mg/kg and atropine 0.02 mg/kg, and then oral secretion was suctioned and the patients were extubated fully awake after return of the protective airway reflexes with full muscle power. Times passed from end of procedure till spontaneous eye opening (from cessation of infusions till spontaneous eye opening), extubation, tongue protrusion, and patient's ability to mention name were recorded. Duration of surgery (time from skin incision till end of procedure) and duration of anaesthesia (time from induction till shifting the patients from operating table to the PACU) were also recorded.
Patients were transferred to the postanesthesia care unit (PACU) where heart rate, arterial blood pressure, respiration, and temperature were continuously monitored by a nurse blind to the study deign to avoid bias. Postoperative pain management included 1 g of paracetamol IV at 8 hr. Assessed of postoperative pain was done using pain numerical rating scale (NRS) on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. NRS is a (0-10) scale, where (0) denotes no pain, whereas (10) refers to maximal pain imagined. Fentanyl (25 μg) IV was used when NRS exceeded 4. Times to first rescue analgesia and total amount of fentanyl consumed were recorded. Recue antiemetic ondansetron (4 mg) IV was given for nausea lasting \> 5 min (persistent) or vomiting and repeated as required. Total dose of ondansetron was noted.
The White-song scoring system a more up to date quick track scoring framework incorporating fundamental fast track variables like physical steadiness, vitals and consciousness level has been proposed to evaluate the recovery profile. Furthermore it involved assessment of adverse events like postoperative pain and vomiting, which were unfortunately missed by the modified Aldrete score. A minimum score (12 / 14) should be established prior to patient safe fast-tracked. It was evaluated on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. Patients reached White-Song score 12 + NRS \< 4 were discharged from PACU. Length of stay in PACU till discharge were also recorded
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
* Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group E
Esmolol group: patients received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery
Esmolol
loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
Group M
Magnesium sulphate group: patients received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Magnesium sulfate
loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esmolol
loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
Magnesium sulfate
loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* body mass index \>35 kg/m2,
* significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases
* liver or renal disease,
* known asthma or reactive airway diseases.
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria University Faculty of Medicin
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0305810
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.